Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Statistics
Share Statistics
Ligand Pharmaceuticals has 19.26M shares outstanding. The number of shares has increased by 7.19% in one year.
Shares Outstanding | 19.26M |
Shares Change (YoY) | 7.19% |
Shares Change (QoQ) | 1.91% |
Owned by Institutions (%) | 98.92% |
Shares Floating | 18.78M |
Failed to Deliver (FTD) Shares | 49 |
FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 911.39K, so 4.82% of the outstanding shares have been sold short.
Short Interest | 911.39K |
Short % of Shares Out | 4.82% |
Short % of Float | 4.93% |
Short Ratio (days to cover) | 7.07 |
Valuation Ratios
The PE ratio is -486.05 and the forward PE ratio is 19.25. Ligand Pharmaceuticals's PEG ratio is 4.53.
PE Ratio | -486.05 |
Forward PE | 19.25 |
PS Ratio | 11.73 |
Forward PS | 5.7 |
PB Ratio | 2.36 |
P/FCF Ratio | 20.58 |
PEG Ratio | 4.53 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.01.
Current Ratio | 8.93 |
Quick Ratio | 8.55 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.17 |
Debt / FCF | 0.07 |
Interest Coverage | -7.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $2.46M |
Profits Per Employee | $-59.29K |
Employee Count | 68 |
Asset Turnover | 0.18 |
Inventory Turnover | 0.78 |
Taxes
Income Tax | -6.55M |
Effective Tax Rate | -260.13% |
Stock Price Statistics
The stock price has increased by 42.79% in the last 52 weeks. The beta is 1.03, so Ligand Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.03 |
52-Week Price Change | 42.79% |
50-Day Moving Average | 113.76 |
200-Day Moving Average | 107.26 |
Relative Strength Index (RSI) | 40.56 |
Average Volume (20 Days) | 107.92K |
Income Statement
In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.
Revenue | 167.13M |
Gross Profit | 156.06M |
Operating Income | -22.61M |
Net Income | -4.03M |
EBITDA | 40.79M |
EBIT | 5.55M |
Earnings Per Share (EPS) | -0.22 |
Balance Sheet
The company has 72.31M in cash and 7.11M in debt, giving a net cash position of 65.2M.
Cash & Cash Equivalents | 72.31M |
Total Debt | 7.11M |
Net Cash | 65.2M |
Retained Earnings | 498.98M |
Total Assets | 941.77M |
Working Capital | 294.45M |
Cash Flow
In the last 12 months, operating cash flow was 97.05M and capital expenditures -1.82M, giving a free cash flow of 95.23M.
Operating Cash Flow | 97.05M |
Capital Expenditures | -1.82M |
Free Cash Flow | 95.23M |
FCF Per Share | 5.21 |
Margins
Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.
Gross Margin | 93.37% |
Operating Margin | -13.53% |
Pretax Margin | 1.51% |
Profit Margin | -2.41% |
EBITDA Margin | 24.41% |
EBIT Margin | -13.53% |
FCF Margin | 56.98% |
Dividends & Yields
LGND does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for LGND is $141.5, which is 35.4% higher than the current price. The consensus rating is "Buy".
Price Target | $141.5 |
Price Target Difference | 35.4% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 2, 2022. It was a forward split with a ratio of 1603:1000.
Last Split Date | Nov 2, 2022 |
Split Type | forward |
Split Ratio | 1603:1000 |
Scores
Altman Z-Score | 11.09 |
Piotroski F-Score | 3 |